KIORA PHARMACEUTICALS INC — Director's Dealing 2018

May 16, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: EYEGATE PHARMACEUTICALS INC (EYEG)
CIK: 0001372514
Period of Report: 2018-05-14

Reporting Person: ARMISTICE CAPITAL, LLC (Director, 10% Owner)
Reporting Person: Armistice Capital Master Fund Ltd. (Director, 10% Owner)
Reporting Person: Boyd Steven (Director, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-05-14	Common Stock	P	5758	$0.5310	Acquired	16732500	Direct
2018-05-14	Common Stock	P	0	—	Acquired	16732500	Indirect
2018-05-14	Common Stock	P	0	—	Acquired	16732500	Indirect
2018-05-14	Common Stock	P	10000	$0.5360	Acquired	16742500	Direct
2018-05-14	Common Stock	P	0	—	Acquired	16742500	Indirect
2018-05-14	Common Stock	P	0	—	Acquired	16742500	Indirect

Footnotes

F1: The reported securities are directly owned by Armistice Capital Master Fund Ltd.

F2: The reported securities are directly owned by Armistice Capital Master Fund Ltd., a Cayman Islands corporation, and may be deemed to be indirectly beneficially owned by Armistice Capital, LLC, as the investment manager of Armistice Capital Master Fund Ltd. The reported securities may also be deemed to be indirectly beneficially owned by Steven Boyd as Managing Member of Armistice Capital, LLC and Director of Armistice Capital Master Fund Ltd. Armistice Capital, LLC and Steven Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interest therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.